FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:GMDS-DUSP22

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: GMDS-DUSP22
FusionPDB ID: 33455
FusionGDB2.0 ID: 33455
HgeneTgene
Gene symbol

GMDS

DUSP22

Gene ID

2762

56940

Gene nameGDP-mannose 4,6-dehydratasedual specificity phosphatase 22
SynonymsGMD|SDR3E1JKAP|JSP-1|JSP1|LMW-DSP2|LMWDSP2|MKP-x|MKPX|VHX
Cytomap

6p25.3

6p25.3

Type of geneprotein-codingprotein-coding
DescriptionGDP-mannose 4,6 dehydrataseGDP-D-mannose dehydrataseshort chain dehydrogenase/reductase family 3E, member 1dual specificity protein phosphatase 22JNK-stimulating phosphatase 1JNK-stimulatory phosphatase-1MAP kinase phosphatase xepididymis secretory sperm binding proteinhomolog of mouse dual specificity phosphatase LMW-DSP2low molecular weight dual specif
Modification date2020031320200313
UniProtAcc

O60547

Main function of 5'-partner protein: FUNCTION: Catalyzes the conversion of GDP-D-mannose to GDP-4-dehydro-6-deoxy-D-mannose. {ECO:0000269|PubMed:9525924}.

Q9NRW4

Main function of 5'-partner protein: FUNCTION: Activates the Jnk signaling pathway. Dephosphorylates and deactivates p38 and stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) (By similarity). {ECO:0000250, ECO:0000269|PubMed:11717427}.
Ensembl transtripts involved in fusion geneENST idsENST00000380815, ENST00000530927, 
ENST00000467288, 
ENST00000603453, 
ENST00000605035, ENST00000419235, 
ENST00000603290, ENST00000604971, 
ENST00000605315, ENST00000605863, 
ENST00000344450, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score28 X 19 X 15=79805 X 4 X 3=60
# samples 325
** MAII scorelog2(32/7980*10)=-4.64024493622235
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(5/60*10)=-0.263034405833794
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
Fusion gene context

PubMed: GMDS [Title/Abstract] AND DUSP22 [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: GMDS [Title/Abstract] AND DUSP22 [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)GMDS(1930337)-DUSP22(304628), # samples:1
Anticipated loss of major functional domain due to fusion event.GMDS-DUSP22 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
GMDS-DUSP22 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
HgeneGMDS

GO:0019673

GDP-mannose metabolic process

9525924

HgeneGMDS

GO:0042351

'de novo' GDP-L-fucose biosynthetic process

9525924

TgeneDUSP22

GO:0035335

peptidyl-tyrosine dephosphorylation

20018849

TgeneDUSP22

GO:0051895

negative regulation of focal adhesion assembly

20018849

TgeneDUSP22

GO:0071364

cellular response to epidermal growth factor stimulus

20018849



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr6:1930337/chr6:304628)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across GMDS (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across DUSP22 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000530927GMDSchr61930337-ENST00000344450DUSP22chr6304628+1750729481262404
ENST00000380815GMDSchr61930337-ENST00000344450DUSP22chr6304628+20621041421574510

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000530927ENST00000344450GMDSchr61930337-DUSP22chr6304628+0.0007169860.999283
ENST00000380815ENST00000344450GMDSchr61930337-DUSP22chr6304628+0.001616130.9983839

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for GMDS-DUSP22

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
GMDSchr61930337DUSP22chr63046281041333AKRDWGHAKDYVEILPGLYIGNFKDA
GMDSchr61930337DUSP22chr6304628729227AKRDWGHAKDYVEILPGLYIGNFKDA

Top

Potential FusionNeoAntigen Information of GMDS-DUSP22 in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
GMDS-DUSP22_1930337_304628.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
GMDS-DUSP22chr61930337chr63046281041HLA-B18:01VEILPGLY0.99160.85071119
GMDS-DUSP22chr61930337chr63046281041HLA-B39:01GHAKDYVEI0.99830.7541514
GMDS-DUSP22chr61930337chr63046281041HLA-B38:02GHAKDYVEI0.99750.8641514
GMDS-DUSP22chr61930337chr63046281041HLA-B38:01GHAKDYVEI0.99740.8745514
GMDS-DUSP22chr61930337chr63046281041HLA-B13:01VEILPGLYI0.97040.73541120
GMDS-DUSP22chr61930337chr63046281041HLA-B14:01HAKDYVEIL0.96110.5095615
GMDS-DUSP22chr61930337chr63046281041HLA-B14:02HAKDYVEIL0.96110.5095615
GMDS-DUSP22chr61930337chr63046281041HLA-B15:02YVEILPGLY0.91860.85171019
GMDS-DUSP22chr61930337chr63046281041HLA-B35:03HAKDYVEIL0.91190.8333615
GMDS-DUSP22chr61930337chr63046281041HLA-B35:02HAKDYVEIL0.78160.9164615
GMDS-DUSP22chr61930337chr63046281041HLA-B35:04HAKDYVEIL0.78160.9164615
GMDS-DUSP22chr61930337chr63046281041HLA-B41:01VEILPGLYI0.22850.79951120
GMDS-DUSP22chr61930337chr63046281041HLA-B52:01VEILPGLYI0.02780.60871120
GMDS-DUSP22chr61930337chr63046281041HLA-B39:13VEILPGLYI0.01340.72451120
GMDS-DUSP22chr61930337chr63046281041HLA-B39:01GHAKDYVEIL0.99490.8277515
GMDS-DUSP22chr61930337chr63046281041HLA-B38:02GHAKDYVEIL0.9890.8917515
GMDS-DUSP22chr61930337chr63046281041HLA-B38:01GHAKDYVEIL0.98640.899515
GMDS-DUSP22chr61930337chr63046281041HLA-B51:07HAKDYVEI0.99470.8077614
GMDS-DUSP22chr61930337chr63046281041HLA-C03:19HAKDYVEIL0.99960.9734615
GMDS-DUSP22chr61930337chr63046281041HLA-C03:07HAKDYVEIL0.99960.9522615
GMDS-DUSP22chr61930337chr63046281041HLA-C03:08HAKDYVEIL0.99950.7805615
GMDS-DUSP22chr61930337chr63046281041HLA-C15:04HAKDYVEIL0.99950.8522615
GMDS-DUSP22chr61930337chr63046281041HLA-C15:06HAKDYVEIL0.99910.8758615
GMDS-DUSP22chr61930337chr63046281041HLA-C12:12HAKDYVEIL0.9970.8826615
GMDS-DUSP22chr61930337chr63046281041HLA-B39:05GHAKDYVEI0.9970.7295514
GMDS-DUSP22chr61930337chr63046281041HLA-C06:03HAKDYVEIL0.99630.9759615
GMDS-DUSP22chr61930337chr63046281041HLA-C12:04HAKDYVEIL0.99590.9744615
GMDS-DUSP22chr61930337chr63046281041HLA-C12:16HAKDYVEIL0.99380.9195615
GMDS-DUSP22chr61930337chr63046281041HLA-C04:06HAKDYVEIL0.98630.7243615
GMDS-DUSP22chr61930337chr63046281041HLA-C08:13HAKDYVEIL0.96740.915615
GMDS-DUSP22chr61930337chr63046281041HLA-C08:04HAKDYVEIL0.96740.915615
GMDS-DUSP22chr61930337chr63046281041HLA-B15:31YVEILPGLY0.95550.76131019
GMDS-DUSP22chr61930337chr63046281041HLA-C03:14HAKDYVEIL0.87210.9519615
GMDS-DUSP22chr61930337chr63046281041HLA-B14:03HAKDYVEIL0.82890.6023615
GMDS-DUSP22chr61930337chr63046281041HLA-C07:05HAKDYVEIL0.81910.9397615
GMDS-DUSP22chr61930337chr63046281041HLA-C07:13HAKDYVEIL0.81520.8814615
GMDS-DUSP22chr61930337chr63046281041HLA-C08:03HAKDYVEIL0.78470.9601615
GMDS-DUSP22chr61930337chr63046281041HLA-B35:12HAKDYVEIL0.78160.9164615
GMDS-DUSP22chr61930337chr63046281041HLA-C02:06HAKDYVEIL0.78030.9195615
GMDS-DUSP22chr61930337chr63046281041HLA-C07:29HAKDYVEIL0.75380.891615
GMDS-DUSP22chr61930337chr63046281041HLA-C07:27HAKDYVEIL0.73630.923615
GMDS-DUSP22chr61930337chr63046281041HLA-C07:95HAKDYVEIL0.66840.6471615
GMDS-DUSP22chr61930337chr63046281041HLA-B39:10HAKDYVEIL0.64490.8215615
GMDS-DUSP22chr61930337chr63046281041HLA-B51:07HAKDYVEIL0.60660.7867615
GMDS-DUSP22chr61930337chr63046281041HLA-B51:07VEILPGLYI0.02380.52821120
GMDS-DUSP22chr61930337chr63046281041HLA-B39:05GHAKDYVEIL0.98920.8065515
GMDS-DUSP22chr61930337chr63046281041HLA-B18:08VEILPGLY0.9950.66661119
GMDS-DUSP22chr61930337chr63046281041HLA-B18:06VEILPGLY0.99350.85871119
GMDS-DUSP22chr61930337chr63046281041HLA-B18:04VEILPGLY0.99160.87121119
GMDS-DUSP22chr61930337chr63046281041HLA-B18:05VEILPGLY0.99160.85071119
GMDS-DUSP22chr61930337chr63046281041HLA-B18:03VEILPGLY0.97580.84211119
GMDS-DUSP22chr61930337chr63046281041HLA-B18:11VEILPGLY0.96110.77451119
GMDS-DUSP22chr61930337chr63046281041HLA-C03:03HAKDYVEIL0.99970.975615
GMDS-DUSP22chr61930337chr63046281041HLA-C03:04HAKDYVEIL0.99970.975615
GMDS-DUSP22chr61930337chr63046281041HLA-C15:09HAKDYVEIL0.99950.8522615
GMDS-DUSP22chr61930337chr63046281041HLA-C03:05HAKDYVEIL0.99930.8911615
GMDS-DUSP22chr61930337chr63046281041HLA-C03:17HAKDYVEIL0.99920.9408615
GMDS-DUSP22chr61930337chr63046281041HLA-C03:67HAKDYVEIL0.99880.9613615
GMDS-DUSP22chr61930337chr63046281041HLA-C15:05HAKDYVEIL0.99870.8879615
GMDS-DUSP22chr61930337chr63046281041HLA-C15:02HAKDYVEIL0.99860.8346615
GMDS-DUSP22chr61930337chr63046281041HLA-B39:31GHAKDYVEI0.99840.7626514
GMDS-DUSP22chr61930337chr63046281041HLA-C03:02HAKDYVEIL0.99810.9407615
GMDS-DUSP22chr61930337chr63046281041HLA-B38:05GHAKDYVEI0.99740.8745514
GMDS-DUSP22chr61930337chr63046281041HLA-C12:03HAKDYVEIL0.99670.9444615
GMDS-DUSP22chr61930337chr63046281041HLA-C16:04HAKDYVEIL0.99580.9454615
GMDS-DUSP22chr61930337chr63046281041HLA-C12:02HAKDYVEIL0.99430.9168615
GMDS-DUSP22chr61930337chr63046281041HLA-C06:02HAKDYVEIL0.99330.9735615
GMDS-DUSP22chr61930337chr63046281041HLA-C06:17HAKDYVEIL0.99330.9735615
GMDS-DUSP22chr61930337chr63046281041HLA-C03:06HAKDYVEIL0.99260.9785615
GMDS-DUSP22chr61930337chr63046281041HLA-B40:04VEILPGLYI0.97320.54751120
GMDS-DUSP22chr61930337chr63046281041HLA-C06:06HAKDYVEIL0.96910.9811615
GMDS-DUSP22chr61930337chr63046281041HLA-B15:30HAKDYVEIL0.95890.6447615
GMDS-DUSP22chr61930337chr63046281041HLA-C07:04HAKDYVEIL0.95660.8887615
GMDS-DUSP22chr61930337chr63046281041HLA-B15:09GHAKDYVEI0.94460.6525514
GMDS-DUSP22chr61930337chr63046281041HLA-B35:43HAKDYVEIL0.94360.7385615
GMDS-DUSP22chr61930337chr63046281041HLA-B35:13HAKDYVEIL0.90660.8444615
GMDS-DUSP22chr61930337chr63046281041HLA-C16:02HAKDYVEIL0.88760.9814615
GMDS-DUSP22chr61930337chr63046281041HLA-C07:22HAKDYVEIL0.84720.616615
GMDS-DUSP22chr61930337chr63046281041HLA-C16:01HAKDYVEIL0.80220.9567615
GMDS-DUSP22chr61930337chr63046281041HLA-C08:01HAKDYVEIL0.78470.9601615
GMDS-DUSP22chr61930337chr63046281041HLA-B35:09HAKDYVEIL0.78160.9164615
GMDS-DUSP22chr61930337chr63046281041HLA-C02:02HAKDYVEIL0.73780.9319615
GMDS-DUSP22chr61930337chr63046281041HLA-C02:10HAKDYVEIL0.73780.9319615
GMDS-DUSP22chr61930337chr63046281041HLA-C07:01HAKDYVEIL0.67740.6313615
GMDS-DUSP22chr61930337chr63046281041HLA-B39:11GHAKDYVEI0.66260.5373514
GMDS-DUSP22chr61930337chr63046281041HLA-C06:08HAKDYVEIL0.65220.9598615
GMDS-DUSP22chr61930337chr63046281041HLA-B07:13HAKDYVEIL0.55930.6317615
GMDS-DUSP22chr61930337chr63046281041HLA-C17:01HAKDYVEIL0.30580.84615
GMDS-DUSP22chr61930337chr63046281041HLA-B39:02VEILPGLYI0.0210.73481120
GMDS-DUSP22chr61930337chr63046281041HLA-B38:05GHAKDYVEIL0.98640.899515
GMDS-DUSP22chr61930337chr63046281041HLA-B39:11GHAKDYVEIL0.84940.6966515

Top

Potential FusionNeoAntigen Information of GMDS-DUSP22 in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
GMDS-DUSP22_1930337_304628.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
GMDS-DUSP22chr61930337chr63046281041DRB1-0101AKDYVEILPGLYIGN722
GMDS-DUSP22chr61930337chr63046281041DRB1-0101KDYVEILPGLYIGNF823
GMDS-DUSP22chr61930337chr63046281041DRB1-0102AKDYVEILPGLYIGN722
GMDS-DUSP22chr61930337chr63046281041DRB1-0102KDYVEILPGLYIGNF823
GMDS-DUSP22chr61930337chr63046281041DRB1-0102HAKDYVEILPGLYIG621
GMDS-DUSP22chr61930337chr63046281041DRB1-0105AKDYVEILPGLYIGN722
GMDS-DUSP22chr61930337chr63046281041DRB1-0105KDYVEILPGLYIGNF823
GMDS-DUSP22chr61930337chr63046281041DRB1-0107AKDYVEILPGLYIGN722
GMDS-DUSP22chr61930337chr63046281041DRB1-0107KDYVEILPGLYIGNF823
GMDS-DUSP22chr61930337chr63046281041DRB1-0109AKDYVEILPGLYIGN722
GMDS-DUSP22chr61930337chr63046281041DRB1-0111AKDYVEILPGLYIGN722
GMDS-DUSP22chr61930337chr63046281041DRB1-0111KDYVEILPGLYIGNF823
GMDS-DUSP22chr61930337chr63046281041DRB1-0115AKDYVEILPGLYIGN722
GMDS-DUSP22chr61930337chr63046281041DRB1-0115KDYVEILPGLYIGNF823
GMDS-DUSP22chr61930337chr63046281041DRB1-0119AKDYVEILPGLYIGN722
GMDS-DUSP22chr61930337chr63046281041DRB1-0119KDYVEILPGLYIGNF823
GMDS-DUSP22chr61930337chr63046281041DRB1-0123AKDYVEILPGLYIGN722
GMDS-DUSP22chr61930337chr63046281041DRB1-0123KDYVEILPGLYIGNF823
GMDS-DUSP22chr61930337chr63046281041DRB1-0125AKDYVEILPGLYIGN722
GMDS-DUSP22chr61930337chr63046281041DRB1-0125KDYVEILPGLYIGNF823
GMDS-DUSP22chr61930337chr63046281041DRB1-0127AKDYVEILPGLYIGN722
GMDS-DUSP22chr61930337chr63046281041DRB1-0127KDYVEILPGLYIGNF823
GMDS-DUSP22chr61930337chr63046281041DRB1-0129AKDYVEILPGLYIGN722
GMDS-DUSP22chr61930337chr63046281041DRB1-0129KDYVEILPGLYIGNF823
GMDS-DUSP22chr61930337chr63046281041DRB1-0131AKDYVEILPGLYIGN722
GMDS-DUSP22chr61930337chr63046281041DRB1-0131KDYVEILPGLYIGNF823
GMDS-DUSP22chr61930337chr63046281041DRB1-0825AKDYVEILPGLYIGN722
GMDS-DUSP22chr61930337chr63046281041DRB1-1201AKDYVEILPGLYIGN722
GMDS-DUSP22chr61930337chr63046281041DRB1-1201KDYVEILPGLYIGNF823
GMDS-DUSP22chr61930337chr63046281041DRB1-1201HAKDYVEILPGLYIG621
GMDS-DUSP22chr61930337chr63046281041DRB1-1203AKDYVEILPGLYIGN722
GMDS-DUSP22chr61930337chr63046281041DRB1-1203KDYVEILPGLYIGNF823
GMDS-DUSP22chr61930337chr63046281041DRB1-1203HAKDYVEILPGLYIG621
GMDS-DUSP22chr61930337chr63046281041DRB1-1205AKDYVEILPGLYIGN722
GMDS-DUSP22chr61930337chr63046281041DRB1-1205KDYVEILPGLYIGNF823
GMDS-DUSP22chr61930337chr63046281041DRB1-1205HAKDYVEILPGLYIG621
GMDS-DUSP22chr61930337chr63046281041DRB1-1206AKDYVEILPGLYIGN722
GMDS-DUSP22chr61930337chr63046281041DRB1-1206KDYVEILPGLYIGNF823
GMDS-DUSP22chr61930337chr63046281041DRB1-1206HAKDYVEILPGLYIG621
GMDS-DUSP22chr61930337chr63046281041DRB1-1207AKDYVEILPGLYIGN722
GMDS-DUSP22chr61930337chr63046281041DRB1-1207KDYVEILPGLYIGNF823
GMDS-DUSP22chr61930337chr63046281041DRB1-1207HAKDYVEILPGLYIG621
GMDS-DUSP22chr61930337chr63046281041DRB1-1208AKDYVEILPGLYIGN722
GMDS-DUSP22chr61930337chr63046281041DRB1-1208KDYVEILPGLYIGNF823
GMDS-DUSP22chr61930337chr63046281041DRB1-1208HAKDYVEILPGLYIG621
GMDS-DUSP22chr61930337chr63046281041DRB1-1210AKDYVEILPGLYIGN722
GMDS-DUSP22chr61930337chr63046281041DRB1-1210KDYVEILPGLYIGNF823
GMDS-DUSP22chr61930337chr63046281041DRB1-1210HAKDYVEILPGLYIG621
GMDS-DUSP22chr61930337chr63046281041DRB1-1211AKDYVEILPGLYIGN722
GMDS-DUSP22chr61930337chr63046281041DRB1-1211KDYVEILPGLYIGNF823
GMDS-DUSP22chr61930337chr63046281041DRB1-1211HAKDYVEILPGLYIG621
GMDS-DUSP22chr61930337chr63046281041DRB1-1212AKDYVEILPGLYIGN722
GMDS-DUSP22chr61930337chr63046281041DRB1-1212KDYVEILPGLYIGNF823
GMDS-DUSP22chr61930337chr63046281041DRB1-1212HAKDYVEILPGLYIG621
GMDS-DUSP22chr61930337chr63046281041DRB1-1213AKDYVEILPGLYIGN722
GMDS-DUSP22chr61930337chr63046281041DRB1-1213KDYVEILPGLYIGNF823
GMDS-DUSP22chr61930337chr63046281041DRB1-1213HAKDYVEILPGLYIG621
GMDS-DUSP22chr61930337chr63046281041DRB1-1214AKDYVEILPGLYIGN722
GMDS-DUSP22chr61930337chr63046281041DRB1-1214KDYVEILPGLYIGNF823
GMDS-DUSP22chr61930337chr63046281041DRB1-1214HAKDYVEILPGLYIG621
GMDS-DUSP22chr61930337chr63046281041DRB1-1215AKDYVEILPGLYIGN722
GMDS-DUSP22chr61930337chr63046281041DRB1-1215KDYVEILPGLYIGNF823
GMDS-DUSP22chr61930337chr63046281041DRB1-1215HAKDYVEILPGLYIG621
GMDS-DUSP22chr61930337chr63046281041DRB1-1216AKDYVEILPGLYIGN722
GMDS-DUSP22chr61930337chr63046281041DRB1-1216HAKDYVEILPGLYIG621
GMDS-DUSP22chr61930337chr63046281041DRB1-1216KDYVEILPGLYIGNF823
GMDS-DUSP22chr61930337chr63046281041DRB1-1217AKDYVEILPGLYIGN722
GMDS-DUSP22chr61930337chr63046281041DRB1-1217KDYVEILPGLYIGNF823
GMDS-DUSP22chr61930337chr63046281041DRB1-1217HAKDYVEILPGLYIG621
GMDS-DUSP22chr61930337chr63046281041DRB1-1218AKDYVEILPGLYIGN722
GMDS-DUSP22chr61930337chr63046281041DRB1-1218KDYVEILPGLYIGNF823
GMDS-DUSP22chr61930337chr63046281041DRB1-1218HAKDYVEILPGLYIG621
GMDS-DUSP22chr61930337chr63046281041DRB1-1219AKDYVEILPGLYIGN722
GMDS-DUSP22chr61930337chr63046281041DRB1-1219KDYVEILPGLYIGNF823
GMDS-DUSP22chr61930337chr63046281041DRB1-1220AKDYVEILPGLYIGN722
GMDS-DUSP22chr61930337chr63046281041DRB1-1221AKDYVEILPGLYIGN722
GMDS-DUSP22chr61930337chr63046281041DRB1-1221KDYVEILPGLYIGNF823
GMDS-DUSP22chr61930337chr63046281041DRB1-1221HAKDYVEILPGLYIG621
GMDS-DUSP22chr61930337chr63046281041DRB1-1222AKDYVEILPGLYIGN722
GMDS-DUSP22chr61930337chr63046281041DRB1-1222KDYVEILPGLYIGNF823
GMDS-DUSP22chr61930337chr63046281041DRB1-1222HAKDYVEILPGLYIG621
GMDS-DUSP22chr61930337chr63046281041DRB1-1223AKDYVEILPGLYIGN722
GMDS-DUSP22chr61930337chr63046281041DRB1-1223KDYVEILPGLYIGNF823
GMDS-DUSP22chr61930337chr63046281041DRB1-1223HAKDYVEILPGLYIG621
GMDS-DUSP22chr61930337chr63046281041DRB1-1521KDYVEILPGLYIGNF823
GMDS-DUSP22chr61930337chr63046281041DRB1-1521AKDYVEILPGLYIGN722
GMDS-DUSP22chr61930337chr63046281041DRB1-1615AKDYVEILPGLYIGN722
GMDS-DUSP22chr61930337chr63046281041DRB1-1615KDYVEILPGLYIGNF823

Top

Fusion breakpoint peptide structures of GMDS-DUSP22

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
3266HAKDYVEILPGLYIGMDSDUSP22chr61930337chr63046281041

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of GMDS-DUSP22

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN3266HAKDYVEILPGLYI-7.9962-8.1096
HLA-B14:023BVN3266HAKDYVEILPGLYI-5.70842-6.74372
HLA-B52:013W393266HAKDYVEILPGLYI-6.83737-6.95077
HLA-B52:013W393266HAKDYVEILPGLYI-4.4836-5.5189
HLA-A11:014UQ23266HAKDYVEILPGLYI-10.0067-10.1201
HLA-A11:014UQ23266HAKDYVEILPGLYI-9.03915-10.0745
HLA-A24:025HGA3266HAKDYVEILPGLYI-6.56204-6.67544
HLA-A24:025HGA3266HAKDYVEILPGLYI-5.42271-6.45801
HLA-B44:053DX83266HAKDYVEILPGLYI-7.85648-8.89178
HLA-B44:053DX83266HAKDYVEILPGLYI-5.3978-5.5112
HLA-A02:016TDR3266HAKDYVEILPGLYI-3.37154-4.40684

Top

Vaccine Design for the FusionNeoAntigens of GMDS-DUSP22

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
GMDS-DUSP22chr61930337chr63046281019YVEILPGLYTATGTGGAGATCCTGCCCGGCCTGTAC
GMDS-DUSP22chr61930337chr63046281119VEILPGLYGTGGAGATCCTGCCCGGCCTGTAC
GMDS-DUSP22chr61930337chr63046281120VEILPGLYIGTGGAGATCCTGCCCGGCCTGTACATC
GMDS-DUSP22chr61930337chr6304628514GHAKDYVEIGGCCATGCCAAGGACTATGTGGAGATC
GMDS-DUSP22chr61930337chr6304628515GHAKDYVEILGGCCATGCCAAGGACTATGTGGAGATCCTG
GMDS-DUSP22chr61930337chr6304628614HAKDYVEICATGCCAAGGACTATGTGGAGATC
GMDS-DUSP22chr61930337chr6304628615HAKDYVEILCATGCCAAGGACTATGTGGAGATCCTG

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
GMDS-DUSP22chr61930337chr6304628621HAKDYVEILPGLYIGCATGCCAAGGACTATGTGGAGATCCTGCCCGGCCTGTACATCGGC
GMDS-DUSP22chr61930337chr6304628722AKDYVEILPGLYIGNGCCAAGGACTATGTGGAGATCCTGCCCGGCCTGTACATCGGCAAC
GMDS-DUSP22chr61930337chr6304628823KDYVEILPGLYIGNFAAGGACTATGTGGAGATCCTGCCCGGCCTGTACATCGGCAACTTC

Top

Information of the samples that have these potential fusion neoantigens of GMDS-DUSP22

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
Non-CancerGMDS-DUSP22chr61930337ENST00000380815chr6304628ENST00000344450TCGA-BR-7851-11A

Top

Potential target of CAR-T therapy development for GMDS-DUSP22

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to GMDS-DUSP22

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to GMDS-DUSP22

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource